

Clinical Policy: Mitapivat (Pyrukynd)

Reference Number: CP.PHAR.558

Effective Date: 02.17.22

Last Review Date: 11.24

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Mitapivat (Pyrukynd[®]) is an pyruvate kinase (PK) activator.

FDA Approved Indication(s)

Pyrukynd is indicated for the treatment of hemolytic anemia in adults with PK deficiency.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Pyrukynd is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Pyruvate Kinase Deficiency (must meet all):**

1. Diagnosis of PK deficiency confirmed by *PLKR* gene molecular analysis and one of the following (a or b):
 - a. Presence of at least 2 mutant alleles in the *PKLR* gene, of which at least 1 is a missense mutation;
 - b. Hemolytic anemia with laboratory evidence of reduced red blood cell PK enzymatic activity;
2. Prescribed by or in consultation with a hematologist;
3. Age \geq 18 years;
4. Member is not homozygous for the R479H mutation or have 2 non-missense mutations (without the presence of another missense mutation) in the *PKLR* gene;
5. If member received no more than 4 blood transfusions in the last 12 months, recent (within the last 30 days) hemoglobin concentration \leq 10 g/dL;
6. Prescribed concurrently with oral folic acid;
7. Dose does not exceed both of the following (a and b):
 - a. 100 mg per day;
 - b. 2 tablets per day.

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

- a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Pyruvate Kinase Deficiency (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters:
 - a. Reduced transfusion burden;
 - b. Increase in hemoglobin of at least 1.5 g/dL from baseline prior to Pyrukynd initiation;
3. If request is for a dose increase, new dose does not exceed both of the following (a and b):
 - a. 100 mg per day;
 - b. 2 tablets per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

PK: pyruvate kinase

PKLR: pyruvate kinase liver and red blood cell

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- Patients who were homozygous for the c.1436G>A (p.R479H) variant or had 2 non-missense variants (without the presence of another missense variant) in the *PKLR* gene were excluded in the clinical trial because these patients did not achieve hemoglobin response (change from baseline in Hb \geq 1.5 g/dL at > 50% assessments) in the dose-ranging study.
- The 2024 International expert guidelines for PK deficiency recommend diagnostic confirmation with gene molecular analysis of the *PLKR* gene. If there aren't two known pathogenic mutations in *PLKR* identified, then the panel recommends confirmation of a diagnosis of PK deficiency with PK enzyme activity measurement. This is because confirmatory reduced PK enzyme activity should be obtained where possible to confirm pathogenicity of novel *PKLR* variants or variants of unknown significance detected by molecular testing.

V. Dosage and Administration

| Indication | Dosing Regimen | Maximum Dose |
|---------------|---|--------------|
| PK deficiency | Initial: 5 mg PO BID Dose may be increased every 4 weeks based on response and tolerance to 20 mg BID up to a maximum of 50 mg BID | 100 mg/day |

VI. Product Availability

Oral tablets: 5 mg, 20 mg, 50 mg

VII. References

1. Pyrukynd Prescribing Information. Cambridge, MA: Agios Pharmaceuticals, Inc.; February 2022. Available at <https://www.agios.com/prescribinginfo.pdf>. Accessed July 19, 2024.
2. Al-Samkari H, Galactéros F, Glenthøj A, et al. Mitapivat versus placebo for pyruvate kinase deficiency. *N Engl J Med.* 2022;386(15):1432-1442..
3. Glenthøj A, van Beers EJ, Al-Samkari H, et al. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. *Lancet Haematol.* 2022;9(10):e724-e732. doi:10.1016/S2352-3026(22)00214-9.
4. Grace RF, Barcellini W. Management of pyruvate kinase deficiency in children and adults. *Blood:* September 10, 2020; 136 (11): 1241-1249.
5. Al-Samkari H, Shehata N, Lang-Robertson K, et al. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines. *Lancet Haematol.* 2024;11(3):e228-e239.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|---|----------|-------------------|
| Policy created pre-emptively | 09.28.21 | 11.21 |
| RT4: Converted PEPP to post-FDA-approved status. No significant changes. | 03.08.22 | |
| 4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section. | 08.01.22 | 11.22 |
| 4Q 2023 annual review: no significant changes; references reviewed and updated. | 07.10.23 | 11.23 |
| 4Q 2024 annual review: clarified requirement for <i>PLKR</i> gene molecular analysis for diagnosis of PK deficiency to align with 2024 international expert guidelines; clarified that homozygosity for the R479H mutation and presence of 2 non-missense mutations is specific to the <i>PKLR</i> gene; references reviewed and updated. | 07.19.24 | 11.24 |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or

remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.